Pomerantz LLP

Please review this complaint. Click to Contact Us about joining this ACTION >>

Questions? Ask Us

Sarepta Therapeutics, Inc.

We are investigating Sarepta Therapeutics, Inc. (SRPT) (“Sarepta” or the “Company”) for potential violations of the federal securities laws. 

On August 19, 2019, Sarepta announced receipt of a Complete Response Letter (“CRL”) from the U.S. Food & Drug Administration regarding the Company’s New Drug Application seeking accelerated approval of golodirsen injection for the treatment of Duchenne muscular dystrophy.  Sarepta disclosed that “[t]he CRL generally cites two concerns: the risk of infections related to intravenous infusion ports and renal toxicity seen in pre-clinical models of golodirsen and observed following administration of other antisense oligonucleotides.”  On this news, Sarepta’s stock price fell sharply, damaging investors.